Speaker Profile
M.D., Ph.D., Head of Institute of Medical Oncology, Sheba Medical Center
Biography
Dr. Raanan Berger is director of the Institute of Oncology at the Sheba Medical Center, which is Israel’s national hospital and the largest medical center in the Middle East. His MD and PhD are from Sackler Medical School at the Tel Aviv University, conducting PhD studies with Dr. Gideon Rechavi at the Sheba Medical Center. Dr Berger completed clinical training in Medical Oncology and Radiotherapy at Sheba and Postdoctoral fellowship at Dana Farber Cancer Institute at Harvard Medical School. During this time, he combined clinical work treating prostate cancer patients (with Dr. Philip Kantoff) with basic research in Dr. William C. Hahn’s lab. Dr. Berger developed a novel prostate cancer model derived from primary human prostate epithelial cells with defined genetic elements. In 2006, he established the Riva Koschitzky Oncology Clinical Research Center, at Sheba, which is the largest center for all-phase oncology clinical trials in Israel, currently conducting over 200 advanced clinical trials backed by the biggest pharmaceutical conglomerates and top scientists in the world. Dr Berger led his institute to become one of the most active partners in the world wide initiative networking (WIN) Consortium and he is the PI of the WINTHER-1 trial for personalized cancer medicine.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Predicting clinical response to cancer therapies remains a major challenge in cancer treatment. Recent reports indicate that the tumor microenvironment and heterogeneity can limit the predictive power of current biomarker guided strategies. The panel will discuss new technologies that preserve these critical elements for better predictive value.
